Published in Immun Inflamm Dis on December 07, 2015
RICH2 is implicated in viraemic control of HIV-1 in black South African individuals. Infect Genet Evol (2017) 0.75
Cysteine-linked dimerization of BST-2 confers anoikis resistance to breast cancer cells by negating proapoptotic activities to promote tumor cell survival and growth. Cell Death Dis (2017) 0.75
293tExosome-mediated miR-146a transfer suppresses type I interferon response and facilitates EV71 infection. PLoS Pathog (2017) 0.75
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature (2008) 14.99
The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe (2008) 9.27
Plasmacytoid dendritic cells in immunity. Nat Immunol (2004) 9.11
Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med (2001) 8.60
IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol (2005) 8.33
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature (2009) 6.99
A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science (1988) 6.30
Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol (2008) 6.17
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A (1989) 5.72
Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic (2003) 5.32
Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell (2009) 5.06
Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol (1992) 5.05
Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol (2007) 4.90
HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe (2009) 4.36
Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol (2001) 4.23
Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog (2009) 4.18
Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe (2009) 4.11
Identification of a protein encoded by the vpu gene of HIV-1. Nature (1988) 4.05
Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol (2000) 3.96
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol (2009) 3.67
Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog (2009) 3.66
Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog (2006) 3.57
The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol (1996) 3.56
Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene (2003) 3.53
Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A (2009) 3.47
Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol (2009) 3.13
Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol (1992) 3.06
Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A (2003) 3.05
Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun (1999) 3.03
Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog (2009) 2.92
Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci (2007) 2.90
Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol (2009) 2.87
Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics (1995) 2.65
Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med (2009) 2.63
Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe (2010) 2.44
APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature (2007) 2.28
A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood (1994) 2.27
The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J Virol (1996) 2.21
Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog (2010) 2.12
The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology (2009) 2.11
The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol (1996) 2.10
Innate sensing of HIV-1 assembly by Tetherin induces NFκB-dependent proinflammatory responses. Cell Host Microbe (2012) 2.03
The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J Virol (2009) 2.00
Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol (2005) 1.97
The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog (2010) 1.94
Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog (2010) 1.89
HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J Biol Chem (2009) 1.89
HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology (2010) 1.87
Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog (2010) 1.85
HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J Cell Biol (2004) 1.84
Detection of mammary tumor virus env gene-like sequences in human breast cancer. Cancer Res (1995) 1.75
Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood (2005) 1.75
Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog (2010) 1.73
Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics (2011) 1.71
Human-immunodeficiency-virus-type-1-encoded Vpu protein is phosphorylated by casein kinase II. Eur J Biochem (1992) 1.70
A mouse mammary tumor virus-like long terminal repeat superantigen in human breast cancer. Cancer Res (2004) 1.67
Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol (2012) 1.67
APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe (2010) 1.67
CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J Virol (2010) 1.63
Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog (2012) 1.60
Stimulation of NF-κB activity by the HIV restriction factor BST2. J Virol (2012) 1.56
Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci U S A (2011) 1.56
Retroviral retention activates a Syk-dependent HemITAM in human tetherin. Cell Host Microbe (2014) 1.56
The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog (2010) 1.52
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood (2005) 1.51
Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J Virol (2010) 1.48
Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol (2010) 1.47
Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. J Virol (1996) 1.46
In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc Natl Acad Sci U S A (2011) 1.36
Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J Virol (2011) 1.35
Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS Res Hum Retroviruses (2009) 1.35
Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology (2010) 1.34
Perforin and lymphocyte-mediated cytolysis. Immunol Rev (1995) 1.34
IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. AIDS (2008) 1.33
HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. MBio (2011) 1.30
Immunological changes in primary HIV-1 infection. AIDS (1990) 1.30
Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer (2009) 1.29
Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proc Natl Acad Sci U S A (2010) 1.29
Quantitative multicolor super-resolution microscopy reveals tetherin HIV-1 interaction. PLoS Pathog (2011) 1.29
A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages. Immunology (2010) 1.27
Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (2014) 1.26
Interleukin-27 inhibition of HIV-1 involves an intermediate induction of type I interferon. Blood (2009) 1.23
HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirology (2014) 1.22
Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood (2006) 1.21
SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release. PLoS Pathog (2011) 1.20
Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci (2008) 1.19
HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol (2014) 1.19
TLR4-mediated AKT activation is MyD88/TRIF dependent and critical for induction of oxidative phosphorylation and mitochondrial transcription factor A in murine macrophages. J Immunol (2012) 1.18
Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Clin Pathol (2005) 1.18
The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation. PLoS Pathog (2011) 1.18
Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens. J Virol (2011) 1.14
Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology (2011) 1.14
Influenza virus partially counteracts restriction imposed by tetherin/BST-2. J Biol Chem (2012) 1.13
Structural and biophysical analysis of BST-2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release. J Biol Chem (2010) 1.13
Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol (2006) 1.12
T-cell line adaptation of human immunodeficiency virus type 1 strain SF162: effects on envelope, vpu and macrophage-tropism. J Gen Virol (2000) 1.10